Galectin Therapeutics (GALT) Competitors $3.65 +0.01 (+0.27%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.74 +0.09 (+2.44%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GALT vs. URGN, PHAR, MGTX, GYRE, MNMD, ZVRA, DNTH, DAWN, ATAI, and AUTLShould you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Urogen Pharma (URGN), Pharming Group (PHAR), MeiraGTx (MGTX), Gyre Therapeutics (GYRE), Mind Medicine (MindMed) (MNMD), Zevra Therapeutics (ZVRA), Dianthus Therapeutics (DNTH), Day One Biopharmaceuticals (DAWN), atai Life Sciences (ATAI), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Galectin Therapeutics vs. Its Competitors Urogen Pharma Pharming Group MeiraGTx Gyre Therapeutics Mind Medicine (MindMed) Zevra Therapeutics Dianthus Therapeutics Day One Biopharmaceuticals atai Life Sciences Autolus Therapeutics Galectin Therapeutics (NASDAQ:GALT) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Do institutionals & insiders hold more shares of GALT or URGN? 11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by insiders. Comparatively, 5.1% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is GALT or URGN more profitable? Galectin Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -150.68%. Galectin Therapeutics' return on equity of 0.00% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -216.05% Urogen Pharma -150.68%-97,487.15%-49.57% Do analysts recommend GALT or URGN? Galectin Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 64.38%. Urogen Pharma has a consensus target price of $32.86, suggesting a potential upside of 69.37%. Given Urogen Pharma's higher possible upside, analysts clearly believe Urogen Pharma is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, GALT or URGN? Galectin Therapeutics has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$47.05M-$0.72-5.07Urogen Pharma$90.40M9.91-$126.87M-$3.18-6.10 Which has more volatility & risk, GALT or URGN? Galectin Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Does the media favor GALT or URGN? In the previous week, Urogen Pharma had 11 more articles in the media than Galectin Therapeutics. MarketBeat recorded 13 mentions for Urogen Pharma and 2 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 1.21 beat Urogen Pharma's score of 0.47 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryUrogen Pharma beats Galectin Therapeutics on 8 of the 15 factors compared between the two stocks. Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GALT vs. The Competition Export to ExcelMetricGalectin TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.38M$2.46B$5.48B$9.51BDividend YieldN/A1.81%4.73%4.08%P/E Ratio-5.078.9728.6723.80Price / SalesN/A437.63373.9066.65Price / CashN/A157.7635.4557.96Price / Book-2.174.838.275.55Net Income-$47.05M$31.62M$3.24B$259.03M7 Day Performance25.43%-5.28%-3.69%-4.59%1 Month Performance68.20%4.38%4.33%4.46%1 Year Performance64.79%-2.49%25.95%18.03% Galectin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GALTGalectin Therapeutics2.5126 of 5 stars$3.65+0.3%$6.00+64.4%+63.3%$230.38MN/A-5.079Positive NewsURGNUrogen Pharma4.6169 of 5 stars$15.46+1.2%$32.86+112.5%+22.6%$705.49M$90.40M-4.86200News CoverageUpcoming EarningsInsider TradeGap DownHigh Trading VolumePHARPharming Group3.0169 of 5 stars$10.14-1.0%$30.00+195.7%+43.1%$702.52M$297.20M-50.72280News CoveragePositive NewsEarnings ReportGap DownMGTXMeiraGTx4.145 of 5 stars$8.69+0.8%$24.00+176.2%+56.8%$692.75M$33.28M-3.75300GYREGyre TherapeuticsN/A$7.10-1.5%N/A-52.4%$676.00M$100.64M355.1840MNMDMind Medicine (MindMed)1.9042 of 5 stars$9.95+12.0%$25.50+156.3%+0.7%$670.91MN/A-7.7140News CoverageEarnings ReportAnalyst ForecastHigh Trading VolumeZVRAZevra Therapeutics2.0927 of 5 stars$11.73-2.8%$23.71+102.2%+76.3%$659.98M$23.61M-6.1720Trending NewsShort Interest ↑Analyst RevisionDNTHDianthus Therapeutics1.2237 of 5 stars$20.74+1.7%$53.00+155.5%-26.5%$656.06M$6.24M-7.2080Upcoming EarningsDAWNDay One Biopharmaceuticals2.2584 of 5 stars$6.40flat$29.00+353.1%-53.1%$648.72M$131.16M-9.0160Upcoming EarningsATAIatai Life Sciences2.9973 of 5 stars$3.53+9.3%$9.00+155.0%+193.7%$647.09M$310K-3.8880Analyst ForecastShort Interest ↑Analyst RevisionGap DownHigh Trading VolumeAUTLAutolus Therapeutics2.3438 of 5 stars$2.43+0.8%$9.32+283.5%-47.9%$641.40M$10.12M-2.76330Gap Down Related Companies and Tools Related Companies URGN Alternatives PHAR Alternatives MGTX Alternatives GYRE Alternatives MNMD Alternatives ZVRA Alternatives DNTH Alternatives DAWN Alternatives ATAI Alternatives AUTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GALT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GALT Stock Alerts